Lab result explainedHormonesLast updated November 8, 2026

Estradiol blood test: what high and low estradiol (E2) levels mean

Estradiol (E2) (E2) · Reproductive hormone panel (estradiol with FSH, LH, often progesterone, prolactin and testosterone) · reported in pg/mL (picograms per millilitre); SI units pmol/L (1 pg/mL = 3.67 pmol/L)

Estradiol (E2) is the most potent of the three estrogens and the main one made by the ovaries during the reproductive years. It thickens the uterine lining, drives breast development, maintains vaginal and urinary tissue, protects bone, and feeds back to the pituitary to regulate FSH and LH. Men make it too, by converting testosterone with the enzyme aromatase in fat, bone and brain, and it is essential for male bone density and libido. Normal values depend entirely on who you are and when the sample is drawn: roughly 20 to 400 pg/mL across the menstrual cycle, under about 30 pg/mL after menopause, and 10 to 40 pg/mL in men.

A low estradiol in a woman most often means the ovaries have stopped responding (menopause or premature ovarian insufficiency), or that the pituitary has stopped driving them because of low body weight, over-exercise, stress or high prolactin. The symptoms are the familiar ones of estrogen loss: hot flashes, night sweats, vaginal dryness, poor sleep, low mood and, silently, bone loss. A high estradiol in a woman who is not pregnant is usually mid-cycle timing, an ovarian cyst, fertility drugs or hormone therapy, and rarely an estrogen-producing tumour.

In men, estradiol is checked when there is breast enlargement (gynecomastia), when testosterone treatment is being monitored, or when bone density is unexpectedly low. Excess body fat raises estradiol by increasing aromatase activity, and very low estradiol, whether from aromatase inhibitors or very low testosterone, causes bone loss and raised fat mass. Interpreting any estradiol value needs the cycle day, menopausal status, medications and the FSH and LH results alongside it.

E2 at a glance

  • What it is: the main estrogen, made by ovarian follicles in women and from testosterone by aromatase in men and post-menopausal women.
  • Normal (women): early follicular 20–80 pg/mL; mid-cycle peak 150–400; luteal 50–200; post-menopause under 30 (often under 10 on sensitive assays). Labs differ.
  • Normal (men): about 10–40 pg/mL by mass spectrometry; under 10–15 is linked to bone loss, over 40–50 to gynecomastia.
  • Low estradiol with high FSH: ovarian failure (menopause, premature ovarian insufficiency). Low estradiol with low or normal FSH: pituitary or hypothalamic cause.
  • High estradiol: pregnancy, ovulation timing, ovarian cysts, fertility drugs, HRT or contraception, obesity or liver disease (men), rarely a tumour.
  • Next step: check cycle day and medications, read with FSH, LH and (in men) testosterone; day-3 estradiol above 60–80 pg/mL can hide a high FSH.

Have your whole report? Paste it into the free Lab Explainer

Every marker explained in plain language, in context with the others, with questions to bring to your appointment. No account needed.

What E2 measures

In the ovary, FSH stimulates granulosa cells in the developing follicle to convert androgens from the surrounding theca cells into estradiol. Output rises through the follicular phase as the dominant follicle grows, peaks at 150 to 400 pg/mL about a day before ovulation (triggering the LH surge), falls briefly, then rises again to 50 to 200 pg/mL as the corpus luteum makes both estradiol and progesterone, before dropping to trigger the period. After menopause the follicles are gone and the small amount of circulating estradiol comes from aromatase in fat tissue converting adrenal androgens; this is why heavier post-menopausal women have higher estradiol and more estrogen-dependent breast and uterine cancer.

In blood, about 98 percent of estradiol is bound to sex hormone-binding globulin (SHBG) and albumin; the test measures total estradiol in picograms per millilitre (pg/mL; multiply by 3.67 for pmol/L). Standard immunoassays are designed for the reproductive range and are accurate above about 30 to 50 pg/mL, but they overestimate and are imprecise at the low levels found in men, children and post-menopausal women, often reading 15 to 30 pg/mL where the true value is under 10. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the reference method and should be requested in men, children and when monitoring aromatase inhibitor treatment.

Several factors shift the value. The combined pill contains ethinyl estradiol, which most assays do not detect, so estradiol reads very low on the pill even though estrogen exposure is high. Transdermal and oral estradiol HRT both raise measured levels (patches typically give 40 to 100 pg/mL). Biotin supplements interfere with some immunoassays. Estradiol is highest in the morning and rises after alcohol. Fertility drugs (clomiphene, letrozole, gonadotropins) can push it to 1,000 to 4,000 pg/mL during stimulation, and pregnancy to 10,000 to 40,000 pg/mL by the third trimester.

Normal range for E2

Reference ranges vary between labs and by age, sex and pregnancy. Use the range printed on your own report.

GroupTypical range (pg/mL (picograms per millilitre); SI units pmol/L (1 pg/mL = 3.67 pmol/L))Notes
Women, early follicular phase (day 2–4)About 20–80 pg/mLThe baseline used with day-3 FSH; a value above 60–80 suppresses FSH and can mask diminished ovarian reserve.
Women, late follicular and ovulatory peakAbout 150–400 pg/mL (up to 500)Peaks about 24 to 36 hours before ovulation and triggers the LH surge.
Women, luteal phaseAbout 50–200 pg/mLFrom the corpus luteum, with progesterone above 3 ng/mL confirming ovulation.
Women, post-menopauseUnder 30 pg/mL on standard assays; typically under 10 by LC-MS/MSHigher with greater body fat. Values persistently above 30–40 off HRT warrant investigation.
Women, on transdermal or oral estradiol HRTTypically 40–150 pg/mLTarget levels are individualised to symptoms; the combined pill reads low because ethinyl estradiol is not detected.
PregnancyFirst trimester 200–4,000; third trimester 10,000–40,000 pg/mLPlacental production; not used clinically to monitor pregnancy.
Men, adultAbout 10–40 pg/mL (LC-MS/MS)Immunoassays often read 15–60. Under 10–15 associated with bone loss and higher fat mass; above 40–50 with gynecomastia.
Children (prepubertal)Under about 10–15 pg/mLImmunoassays are unreliable here; a sensitive LC-MS/MS method is needed when precocious puberty is suspected.
Fertility stimulation (IVF)Often 1,000–4,000 pg/mL at triggerValues above about 3,500–5,000 raise the risk of ovarian hyperstimulation syndrome.

High estradiol

In a woman with periods, the first question is timing: a value of 300 pg/mL is normal on day 12 and high on day 3. Genuinely high estradiol outside the ovulatory window most often comes from a functional ovarian cyst that keeps producing hormone, from early pregnancy, or from fertility drugs or hormone therapy. A day-3 estradiol above 60 to 80 pg/mL is itself a soft sign of diminishing ovarian reserve: as follicles become fewer, FSH rises earlier and recruits a follicle sooner, so estradiol is already climbing by the time the baseline is drawn and the FSH looks falsely reassuring.

Persistently high estradiol outside these explanations is uncommon and worth taking seriously. Estrogen-producing ovarian tumours (granulosa cell tumours and thecomas) raise estradiol and typically cause irregular or post-menopausal bleeding; in men, Leydig or Sertoli cell tumours of the testis and adrenal tumours can do the same. In post-menopausal women, a measured estradiol above 30 to 40 pg/mL off HRT is more often due to body fat and assay imprecision than a tumour, but with bleeding or a thickened uterine lining it needs an ultrasound and endometrial sampling.

In men, high estradiol mostly reflects more aromatase activity or more substrate. Obesity, alcohol, liver disease (which slows estrogen clearance), hyperthyroidism (which raises SHBG and total estradiol), and testosterone or anabolic steroid use all raise it, and Klinefelter syndrome and ageing shift the testosterone-to-estradiol ratio. The symptom that usually prompts the test is breast tissue enlargement; a high estradiol with a low testosterone, or an estradiol above 50 to 60 pg/mL, is a reason to look for a cause rather than treat the number.

Common causes

  1. Mid-cycle timing and functional ovarian cysts

    The pre-ovulatory peak reaches 150–400 pg/mL for a day or two. Follicular cysts that fail to rupture and corpus luteum cysts continue making estradiol and can delay or disrupt the next period; most resolve within 1 to 3 cycles.

  2. Pregnancy

    Estradiol rises from the first weeks and climbs a hundredfold by term; an unexpectedly high estradiol in a woman of reproductive age should prompt an hCG test before anything else.

  3. Hormone therapy, fertility drugs and contraception

    Transdermal and oral estradiol raise measured levels (patches 40–100 pg/mL, higher with oral gels and high-dose regimens); clomiphene, letrozole and injectable gonadotropins drive multiple follicles and levels of 1,000–4,000 pg/mL. The combined pill does not raise measured estradiol because its ethinyl estradiol is not detected.

  4. Obesity

    Fat tissue is the main site of aromatase outside the gonads. In post-menopausal women, each 5-unit increase in BMI is associated with roughly 30 percent higher estradiol, and in men obesity raises estradiol while lowering testosterone, driving gynecomastia and low libido.

  5. Testosterone therapy and anabolic steroids in men

    Injected testosterone, particularly in large or infrequent doses, is partly aromatised to estradiol; levels above 50–60 pg/mL with breast tenderness are common on high doses. Anabolic steroids such as nandrolone and testosterone esters do the same and suppress the man's own production.

  6. Liver disease

    Cirrhosis reduces estrogen clearance and raises SHBG, so total estradiol rises and testosterone falls; spider naevi, palmar erythema, gynecomastia and testicular shrinkage in men with liver disease reflect this shift.

  7. Hyperthyroidism

    Thyroid hormone excess raises SHBG two to three fold, increasing total (bound) estradiol and testosterone; free hormone is less affected. Gynecomastia occurs in 10–40 percent of men with Graves' disease.

  8. Estrogen-producing tumours

    Granulosa cell tumours and thecomas of the ovary (about 2–5 percent of ovarian tumours) secrete estradiol and inhibin; they present with abnormal or post-menopausal bleeding, a pelvic mass or precocious puberty in girls. Leydig and Sertoli cell tumours of the testis and feminising adrenal tumours are rare causes in men.

  9. Precocious puberty and McCune-Albright syndrome

    Estradiol above the prepubertal range in a girl under 8 with breast development indicates puberty has started; the cause may be central (early activation of the pituitary) or peripheral (an ovarian cyst or tumour, or McCune-Albright syndrome with cafe-au-lait patches and bone lesions).

  10. Environmental or accidental exposure

    Transfer of estradiol gel from a partner, use of estrogen-containing creams, and some lavender or tea tree oil products have been associated with breast development in children; biotin supplements can cause falsely high readings on some assays.

Symptoms that can go with it

  • Breast tenderness, fullness or (in men and children) new breast tissue (gynecomastia)
  • Heavy, prolonged or irregular periods, or bleeding after menopause
  • Bloating, fluid retention and weight gain
  • Headaches or migraine clustering with hormone changes, and mood swings or low mood
  • Worsening of endometriosis or fibroid symptoms (pelvic pain, pressure, heavy bleeding)
  • In men: reduced libido, erectile difficulty, infertility, fat gain and reduced body hair, particularly when testosterone is low
  • In girls under 8: breast development, growth spurt or vaginal bleeding; in boys, breast tissue

Low estradiol

Low estradiol in a woman means the ovaries are not producing much, and the FSH says why. With a high FSH (above 25 to 40 mIU/mL) the ovaries themselves have run down: menopause after about 45, or premature ovarian insufficiency before 40. With a low or normal FSH the pituitary is not driving them: this is the pattern of hypothalamic amenorrhea from low body weight, over-exercise or stress, of high prolactin, and of pituitary disease. In both cases the consequences of estrogen loss are the same: hot flashes, night sweats, sleep disturbance, vaginal dryness and painful sex, urinary symptoms, low mood, joint aches, and over months to years, loss of bone density and a less favourable cholesterol profile.

Premature loss of estrogen matters more than loss at the usual age. Women with premature ovarian insufficiency or hypothalamic amenorrhea lose about 2 to 3 percent of bone density a year while estrogen is low, and both the ESHRE and Endocrine Society guidelines recommend restoring estrogen (by treating the cause, or with HRT or physiological replacement until at least the average age of menopause) to protect bone, heart and brain. Early menopause is also associated with higher cardiovascular mortality. Aromatase inhibitors for breast cancer deliberately drive estradiol to undetectable levels and cause the same bone and joint effects.

In men, estradiol is low when testosterone is low (there is less to aromatise), on aromatase inhibitors (sometimes used off-label in bodybuilding and for fertility), and in rare genetic defects of aromatase or the estrogen receptor. The Finkelstein trial in 2013 showed that estradiol, not testosterone, is the hormone that controls fat accumulation and much of sexual desire in men, and that bone loss accelerates when estradiol falls below about 10 pg/mL. Men who lower estradiol aggressively while on testosterone therapy trade a modest benefit for real harm to bone.

Common causes

  1. Menopause and the menopausal transition

    Follicle depletion after an average age of 51 in the US; estradiol falls below 30 pg/mL (often under 10 on sensitive assays) with FSH above 40. In the transition, estradiol can swing from very high to very low within a single cycle, which accounts for the unpredictability of symptoms.

  2. Premature ovarian insufficiency

    Loss of ovarian function before 40 in about 1 percent of women, from Turner syndrome, fragile X premutation, autoimmune oophoritis, chemotherapy, radiation or surgery, or unexplained; low estradiol with FSH above 25 on two tests 4 weeks apart.

  3. Functional hypothalamic amenorrhea

    Under-eating, weight loss, high training loads or psychological stress suppress GnRH; estradiol is low (often under 30 pg/mL) with low or low-normal FSH and LH and absent periods. The commonest cause of low estradiol in young women who are not pregnant or on contraception.

  4. Hyperprolactinemia

    Prolactin above about 25 ng/mL suppresses GnRH and so FSH, LH and estradiol. Causes include prolactinomas, antipsychotics, metoclopramide, hypothyroidism and kidney disease.

  5. Pituitary and hypothalamic disease

    Tumours, surgery, radiation, Sheehan's syndrome, infiltrative disease and immune checkpoint inhibitors reduce gonadotropin output; estradiol is low with FSH and LH low or inappropriately normal, often with other pituitary hormone deficits.

  6. Aromatase inhibitors, GnRH analogues and other medications

    Letrozole, anastrozole and exemestane for breast cancer lower estradiol by over 90 percent; GnRH agonists and antagonists (leuprolide, elagolix) used for endometriosis, fibroids and before IVF cause a temporary menopause; high-dose progestins, some antiepileptics and chemotherapy also lower it.

  7. Oophorectomy

    Surgical removal of both ovaries produces an abrupt fall to post-menopausal levels within days, with more severe symptoms than natural menopause and, before 45, higher long-term risks of osteoporosis, heart disease and cognitive decline unless estrogen is replaced.

  8. Low testosterone in men

    Because male estradiol is made from testosterone, any cause of low testosterone (primary or secondary hypogonadism, ageing, opioids, pituitary disease) lowers estradiol; men with total testosterone under 200 ng/dL commonly have estradiol under 10–15 pg/mL.

  9. Combined hormonal contraception (apparent low)

    The pill, patch and ring suppress the ovaries' own estradiol to very low levels, and the synthetic ethinyl estradiol they contain is not measured, so the result reads low despite adequate estrogen exposure. It needs no action.

Symptoms that can go with it

  • Hot flashes, night sweats and disturbed sleep
  • Vaginal dryness, burning or itching, pain with sex and recurrent urinary tract infections
  • Irregular, light or absent periods
  • Low mood, anxiety, irritability and poor concentration
  • Joint and muscle aches, dry skin and thinning hair
  • Reduced libido and difficulty with arousal
  • Loss of bone density, stress fractures or an osteoporosis diagnosis at a young age
  • In men: low libido, increased body fat and bone loss despite adequate testosterone

Read it alongside

  • FSH — the key companion test; low estradiol with high FSH means ovarian failure, low estradiol with low FSH means a pituitary or hypothalamic cause, and a day-3 estradiol above 60–80 pg/mL can hide a high FSH.
  • LH — with FSH, confirms where the problem lies; a mid-cycle LH surge follows the estradiol peak by about a day.
  • Progesterone — a day-21 (mid-luteal) progesterone above 3 ng/mL confirms ovulation; estradiol alone cannot.
  • Testosterone and SHBG — in men, the testosterone-to-estradiol ratio and SHBG explain most gynecomastia; in women, high testosterone with normal estradiol points to PCOS.
  • Prolactin and TSH — treatable causes of low estradiol and irregular cycles that are easy to miss.
  • hCG — rules pregnancy in or out before interpreting any unexpected estradiol value in a woman of reproductive age.
  • AMH — a cycle-independent measure of ovarian reserve, more informative than estradiol or FSH for fertility planning.
  • Bone density (DXA) and lipid panel — the long-term consequences of low estradiol; recommended within a few years of premature ovarian insufficiency or prolonged amenorrhea.

What usually happens next

  1. Note the day of your cycle and any hormonal medication (pill, HRT, fertility drugs, testosterone, aromatase inhibitors); most 'abnormal' estradiol results are explained by one of these and need no further action.
  2. If estradiol is low and periods are absent or irregular, expect a pregnancy test, FSH, LH, prolactin and TSH; the FSH result decides whether the ovaries or the pituitary are the issue.
  3. A low estradiol with a high FSH before 40 is repeated after 4 weeks; if confirmed, expect a karyotype, fragile X testing, thyroid and adrenal antibodies, a bone density scan, and a discussion about hormone replacement until at least age 50.
  4. A low estradiol with low or normal FSH prompts a review of weight, eating, training and stress, a prolactin, and if no cause is found, pituitary hormone testing and an MRI.
  5. A high estradiol that is not explained by cycle timing, pregnancy or medication, especially with abnormal bleeding, a pelvic mass or (in men) breast enlargement, leads to a pelvic or testicular ultrasound and sometimes inhibin or tumour markers.
  6. In men being monitored on testosterone therapy, ask for estradiol by LC-MS/MS rather than a standard immunoassay, and be cautious about treating a mildly high value that is not causing symptoms.

Diet, lifestyle and natural levers with evidence

What can move E2 once the cause is known. Nothing here replaces finding the cause.

Restore energy balance and body weight in hypothalamic amenorrhea

Strong evidence

When estradiol is low because of under-eating, weight loss or heavy training, increasing energy intake and reducing training is the treatment: 60 to 80 percent of women regain periods and normal estradiol within 6 to 12 months of regaining lost weight (often back above a BMI of 19 to 20) and moderating exercise, and bone density begins to recover thereafter. The Endocrine Society guideline recommends this approach first, with transdermal estradiol (not the pill) considered for bone protection if recovery is slow.

The combined pill restores bleeding without restoring bone density; do not use it to judge recovery.

Weight loss when overweight (to lower estradiol)

Strong evidence

In a 12-month randomised trial of 439 overweight post-menopausal women, diet-induced weight loss of about 10 percent lowered estradiol by 16 percent and free estradiol by 21 percent, with diet plus exercise giving the largest reductions; losing 10 percent or more of body weight lowered estradiol by about 20 percent. In men with obesity, weight loss raises testosterone and lowers estradiol, and bariatric surgery reduces estradiol by roughly 20 to 30 percent. These changes are large enough to matter for breast cancer risk and gynecomastia.

Limit alcohol

Strong evidence

Alcohol raises estradiol acutely and chronically. In controlled feeding studies, two drinks a day for 8 weeks raised estradiol in post-menopausal women on HRT by about 20 percent and increased estrone sulfate by 7 percent in those not on HRT; pooled analyses of 13 prospective studies found that each 10 g of alcohol a day (about one drink) is associated with 7 to 10 percent higher breast cancer risk, partly through this hormonal effect. In men, heavy drinking raises estradiol, lowers testosterone and is a common contributor to gynecomastia.

Regular aerobic exercise

Moderate evidence

In the ALPHA trial, 320 post-menopausal women randomised to 225 minutes a week of aerobic exercise for a year had estradiol fall by about 8 to 10 percent and SHBG rise, compared with no change in controls, with the effect strongest in those who lost fat. In premenopausal women, moderate exercise has little effect on estradiol unless energy intake falls, and excessive exercise with inadequate fuel lowers it too far (see hypothalamic amenorrhea).

In women with low estradiol from over-training, more exercise is the problem, not the solution.

Higher-fibre, plant-rich diet

Moderate evidence

Dietary fibre binds estrogen excreted in bile and reduces its reabsorption. Controlled feeding studies found that a low-fat, high-fibre diet (over 25 to 30 g of fibre a day) lowered serum estradiol by 10 to 25 percent in premenopausal women within 2 to 3 months, and cohort studies link higher fibre intake with modestly lower post-menopausal estradiol and breast cancer risk. Effects in trials vary and partly reflect accompanying weight loss.

Ground flaxseed (lignans)

Preliminary evidence

Flaxseed is the richest food source of lignans, which are converted by gut bacteria to weak estrogen-like compounds that also inhibit aromatase. Small randomised trials found that 10 to 25 g a day of ground flaxseed for 6 weeks to 3 months lowered estradiol by about 10 to 20 percent in post-menopausal women and lengthened the luteal phase in premenopausal women; a meta-analysis found modest reductions in hot flash frequency that did not reach significance. Evidence is limited to small, short studies.

Flaxseed oil contains no lignans. Whole or ground seed adds 2 to 3 g of fibre per tablespoon and can cause bloating; separate from medications by 1 to 2 hours as it may slow absorption.

When to see a clinician promptly

  • Any vaginal bleeding more than 12 months after your last period, or bleeding in a woman on continuous HRT: must be investigated for endometrial cancer, whatever the estradiol level.
  • Absent periods for 3 months or more in a woman not pregnant or on hormonal contraception, particularly with weight loss, intense exercise, milky nipple discharge or headaches.
  • A high estradiol with a pelvic mass, severe pelvic pain, rapid abdominal swelling or breathlessness during fertility treatment: possible ovarian torsion, a ruptured cyst or ovarian hyperstimulation syndrome.
  • Breast development in a girl under 8 or a boy, or vaginal bleeding in a young girl.
  • In men, breast enlargement that is one-sided, hard, fixed, with nipple discharge or a testicular lump; or new breast tissue with any estradiol result.
  • Low estradiol before the age of 40 (premature ovarian insufficiency or prolonged amenorrhea), because of the long-term risks to bone and heart that early treatment reduces.

Frequently asked questions

What is a normal estradiol level?

It depends on who you are and when the blood was drawn. For a woman with periods: about 20 to 80 pg/mL in the first days of the cycle, 150 to 400 pg/mL just before ovulation, and 50 to 200 pg/mL in the second half. After menopause, under 30 pg/mL on standard assays and typically under 10 on sensitive ones. For men, about 10 to 40 pg/mL by mass spectrometry (standard immunoassays often read higher). Multiply by 3.67 to convert to pmol/L. Always compare with the reference range and cycle phase printed on your report.

What estradiol level indicates menopause?

An estradiol under about 30 pg/mL with an FSH above 25 to 40 mIU/mL fits menopause, but estradiol is a poor menopause test on its own because it swings wildly during the transition, sometimes reaching higher-than-normal values between low ones. Guidelines diagnose menopause from 12 months without periods in women over 45 and reserve blood tests for younger women or those without a cycle history, where FSH is the more informative of the two.

What are the symptoms of low estradiol?

Hot flashes, night sweats and broken sleep; vaginal dryness, painful sex and urinary urgency or infections; light, irregular or absent periods; low mood, anxiety and poor concentration; joint aches, dry skin and thinning hair; and lower libido. Over months to years, low estradiol also causes bone loss that produces no symptoms until a fracture, which is why premature loss of estrogen is treated even when symptoms are mild.

What is a normal estradiol level in men, and what does high estradiol in a man mean?

About 10 to 40 pg/mL by LC-MS/MS; immunoassays are inaccurate at this range and often read 15 to 60. A high estradiol in a man usually comes from more aromatase activity (obesity, alcohol, liver disease) or from testosterone or anabolic steroid use, and causes breast tenderness or gynecomastia, fluid retention and sometimes reduced libido when testosterone is also low. Values over 50 to 60 pg/mL with symptoms warrant a look for the cause. A low estradiol in men (under 10 to 15 pg/mL) causes bone loss and fat gain, so men should not suppress it aggressively.

Is an estradiol of 20, 50 or 300 low or high?

An estradiol of 20 pg/mL is normal on day 2 to 4 of the cycle, low for a woman mid-cycle, high-normal after menopause and normal for a man. A value of 50 is normal in the follicular or luteal phase, a possible sign of early follicle recruitment if drawn on day 3 for fertility, high for a post-menopausal woman off HRT, and high for a man. A value of 300 is a normal pre-ovulatory peak, consistent with early pregnancy or fertility drugs, and otherwise suggests a functional cyst; in a man or post-menopausal woman it needs investigation. Cycle day and context decide.

How can I raise low estradiol naturally?

If the cause is under-eating, weight loss or over-training, restoring energy balance and body weight is the effective and evidence-based route, and most women regain normal estradiol within a year. If the cause is menopause or ovarian insufficiency, no food, herb or supplement meaningfully raises estradiol: soy isoflavones and black cohosh can ease hot flashes in some trials but do not change blood estradiol, and the bone-protective effect requires actual estrogen. Hormone therapy is the treatment with evidence, and for women under 45 it is recommended rather than optional.

How can I lower high estradiol naturally?

The measures with human evidence all work mainly through aromatase in fat and through clearance: losing excess weight (a 10 percent loss lowers estradiol by around 15 to 20 percent in post-menopausal women), cutting alcohol (two drinks a day raises it by up to 20 percent), regular aerobic exercise (about 8 to 10 percent lower over a year), and a higher-fibre diet (10 to 25 percent in short feeding studies). Ground flaxseed has preliminary support. None of these apply to a high estradiol from pregnancy, mid-cycle timing, a cyst or a tumour, which need the right diagnosis rather than diet.

When in my cycle should estradiol be tested?

It depends on the question. For ovarian reserve or a menopause assessment, day 2 to 4 of the cycle, together with FSH. For confirming ovulation, estradiol is not the right test; a progesterone on day 21 (or 7 days before the expected period) is. For tracking fertility treatment, timing is set by the clinic. If you have no periods, any day is fine. Tell the lab about hormonal contraception, HRT, biotin supplements and testosterone, all of which change the result or its interpretation.

References

  1. Estrogen levels test. MedlinePlus, US National Library of Medicine (2023)View source
  2. Finkelstein JS, Lee H, Burnett-Bowie SA, et al.. Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine (2013)
  3. Harlow SD, Gass M, Hall JE, et al.. Executive summary of the Stages of Reproductive Aging Workshop + 10. Journal of Clinical Endocrinology and Metabolism (2012)
  4. European Society for Human Reproduction and Embryology Guideline Group on POI. ESHRE guideline: management of women with premature ovarian insufficiency. Human Reproduction (2016)
  5. Gordon CM, Ackerman KE, Berga SL, et al.. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism (2017)
  6. Campbell KL, Foster-Schubert KE, Alfano CM, et al.. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. Journal of Clinical Oncology (2012)
  7. Friedenreich CM, Woolcott CG, McTiernan A, et al.. Alberta Physical Activity and Breast Cancer Prevention Trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. Journal of Clinical Oncology (2010)
  8. Dorgan JF, Baer DJ, Albert PS, et al.. Effects of moderate alcohol consumption on plasma estradiol and estrone sulfate in postmenopausal women: a controlled feeding study. Journal of the National Cancer Institute (2001)
  9. Endogenous Hormones and Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute (2003)
  10. Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Position statement: utility, limitations, and pitfalls in measuring testosterone and estradiol: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism (2013)
  11. The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause (2022)
  12. Gynecomastia. Merck Manual Professional Version (2024)

Related markers

Related conditions

Evidence guides

Worried about your number?

Ask AskMN what your E2 result could mean in the context of your other results, symptoms and medications. Free, unlimited, no account needed.

Ask about my E2

This page is educational and is not medical advice or a diagnosis. Lab results have to be interpreted together with your history, symptoms and other results by a clinician who knows you. Do not start or stop a supplement to change a lab value before the cause is known.